IRIS
CAVESTRO, Giulia Martina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.492
EU - Europa 2.732
AS - Asia 1.993
AF - Africa 55
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 4
Totale 9.300
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.399
CN - Cina 1.161
SE - Svezia 635
IE - Irlanda 617
SG - Singapore 584
UA - Ucraina 525
FI - Finlandia 402
DE - Germania 288
TR - Turchia 202
GB - Regno Unito 92
CA - Canada 88
IT - Italia 85
CI - Costa d'Avorio 53
BE - Belgio 23
IN - India 18
FR - Francia 16
IR - Iran 13
LT - Lituania 10
RO - Romania 10
NL - Olanda 9
BR - Brasile 8
EU - Europa 7
JP - Giappone 5
VE - Venezuela 4
AU - Australia 3
CZ - Repubblica Ceca 3
ES - Italia 3
GT - Guatemala 3
PE - Perù 3
RU - Federazione Russa 3
CL - Cile 2
HU - Ungheria 2
MD - Moldavia 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
HK - Hong Kong 1
ID - Indonesia 1
LK - Sri Lanka 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PR - Porto Rico 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
TJ - Tagikistan 1
VN - Vietnam 1
Totale 9.300
Salva come PNG Salva come JPEG
Città #
Chandler 859
Dublin 616
Jacksonville 538
Santa Clara 472
Singapore 456
Dearborn 401
Nanjing 251
Boardman 227
Ashburn 212
Beijing 204
Izmir 174
Princeton 154
San Mateo 147
Ann Arbor 122
Shanghai 109
Shenyang 82
Wilmington 81
Toronto 80
Helsinki 67
New York 67
Nanchang 59
Abidjan 53
Hebei 53
Kunming 47
Changsha 41
Hefei 38
Jiaxing 38
Jinan 38
Tianjin 36
Norwalk 29
Kocaeli 26
Woodbridge 26
Parma 24
Brussels 23
Des Moines 18
Hangzhou 18
Los Angeles 18
Guangzhou 17
Houston 16
Pune 16
Zhengzhou 16
Grafing 13
Seattle 12
Bremen 11
Frankfurt am Main 11
Munich 11
Ningbo 11
Auburn Hills 9
Dallas 9
Cambridge 7
Leawood 7
London 7
Rio Saliceto 7
Chengdu 6
Düsseldorf 6
Fremont 6
Haikou 6
Timisoara 6
Taizhou 5
Zanjan 5
Leipzig 4
Maracaibo 4
Milan 4
Ottawa 4
Taiyuan 4
Washington 4
Wenzhou 4
Baotou 3
Calenzano 3
Campina Grande 3
Changchun 3
Chongqing 3
Clifton 3
Espoo 3
Focsani 3
Fuzhou 3
Guatemala City 3
Huzhou 3
Lima 3
Phoenix 3
Redmond 3
Sacramento 3
Shaoxing 3
Taio 3
Tappahannock 3
Andover 2
Augusta 2
Budapest 2
Chaoyang 2
Chisinau 2
College Station 2
Magdeburg 2
Melbourne 2
Mestre 2
Miami 2
Modena 2
Mountain View 2
Natal 2
New Haven 2
Old Bridge 2
Totale 6.236
Salva come PNG Salva come JPEG
Nome #
5 OP Keratin 8 gene mutation in patients with chronic pancreatitis 99
Autonomic balance in inflammatory bowel diseases, irritable bowel syndrome and gastroesophageal reflux disease 94
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? 92
Accuracy of “serological gastric biopsy” in a cohort of dyspeptic patients 88
Association of keratin 8 gene mutation with chronic pancreatitis 87
710 Gastrin-17 (G-17): A Serological Bio-Marker for Diagnosis of Gastro-Esophageal Reflux Disease (GERD) 87
Associations of Spink-1 (N34S) and PRSS-1 (N29I and R122H) gene mutations and chronic pancreatitis in Italy 84
Association of HLA-DRB1 *0401 Allele with chronic pancreatitis 84
P.08.9: The Early Diagnosis of Gastric Cancer: A Six Years Survey Based on 584 Surgical Specimen in Parma Area 83
P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY 80
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 80
Bovine lactoferrin as a rescure treatment for Helicobacter pylori infection: results of a multicenter study 78
PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS 77
S1808 Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR and SPINK-1 in the Clinical Setting of Acute, Acute Recurrent and Chronic Pancreatitis 77
Lactoferrin in a 1-week triple therapy for eradication of H. pylori 76
Study design biases in pancreatic inflammatory diseases. 76
A prospective therapeutical one-year study with pantoprazole for patients with oropharingeal picture of GERD 76
S1921 “GastroPanel Test” in the Clinical Outcome of GERD 76
Rabepmzole in the treatment of non-responders GERD patients: a prospective six-month study 76
Clinical and radiological outcome of patients suffering from chronic pancreatitis associated with gene mutations. 75
Prevalence of H. pylori CagA+ve in suburban area with high incidence of gastric cancer 74
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 74
Usefullness of gastropanel in different topography of H. pylori related chronic gastritis 73
Usefulness of Serum Pepsinogens to Identify Chronic Atrophic Gastritis 73
OC1.09.3 USEFULNESS OF GASTROPANEL FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASES 73
Esophagitis: acute therapy with omeprazole (Single Dosage Versus BID) 73
P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE 73
Gastroprotective effects of Amtolmetin Guacyl: a new non steroidal antiinflammatory drug that activates inducible gastric niytric oxide synthase 72
Topography of gastric damage in H.pylori infection: evaluation by serum pepsinogens levels 72
42 OP Potential use of lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: A pilot study 72
Recovery of gastric function after H. pylori eradication in subjects with body atrophic gastritis: a prospective four years study 72
A new marker for monitoring alcohol abuse? A pilot study on heavy drinkers 72
Associations of spink-1 (N345) and PRSS-1 (N29I AND R122H) gene mutations and chronic pancreatitis in Italy 72
T1651 The Natural History of Gastric Ulcer: A Twenty-Four Years Clinical-Endoscopical Follow-Up 71
Lactoferrin: mechanism of action, clinical significance and therapeutic 70
PANCREATIC PSEUDOCYSTS FOLLOWING ACUTE PANCREATITIS: RISK FACTORS INFLUENCING THERAPEUTIC OUTCOMES 70
Are there useful biomarkers for gastric cancer? 70
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis 70
Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? 70
Clinical Trends and Burden of Death in Gastric Cancer: A Six Years Survey 70
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population 70
7 P Frequency of CFTR gene mutations in consecutive patients suffering from chronic pancreatitis 70
Quality of life in patients with chronic pancreatitis 69
Gastropanel as screening of gastric atrophy in primary care 69
Hypercalcemia due to ectopic secretion of parathyriod related protein from pancreatic carcinoma: a case report 69
Lactoferrin in a one week triple therapy for eradication of H. Pylori 68
Therapy of NERD: single Vs double rabeprazole dosage 68
Efficacy of mesalazine in the treatment of symptomatic diverticular disease 68
Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD) independently of H. pylori status 68
Natural course of functional dyspepsia after after helicobacter pylori eradication a 7-year survey 67
Rabeprazole for the treatment of oropharingeal picture of GERD: a six-month prospective study 67
Nonteroidal drug-related gastroduodenal damage in the elderly 67
PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) 67
M1141 Diagnostic Accuracy of Serum Pepsinogens and Gastrin to Follow-up Helicobacter pylori Infection: A Pilot Study 66
Gastroesophageal reflux disease in celiac patients: Preliminary results in 35 consecutive patients 66
Serum pepsinogen II for early assessment of success of H. pylori eradication 66
Clinical usefulness of serum pepsinogen II in the assessment of H. pylori infection 65
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 65
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. 65
M1260 Effect of Cyclically Long-Term Treatment With Mesalamine in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD): A 5 Years Follow-up Study 65
OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR? 65
Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels 64
Diagnosis of H. pylori gastritis patterns by means of gastropanel 64
Disappearance of gallbladder wall lesions after treatment with ursodeozycolic acid 64
Use of BOVINE lactoferrin for Helicobacter pylori eradication 63
Clinical usefulness of Gastropanel (SPGI, SPGII, GASTRIN-17, HP SPECIFIC IgG) in the assessment of HP infection 63
“GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD 63
Gastro panel® for detection of atrophic gastritis: The “Parma model” 63
Oral sucrose test and serum pepsinogens for evaluation of H. pylori chronic gastritis 63
Pepsinogen I, II, Ratio, and G-17 in Patients With Esophagitis and Patients With Extra-Esophageal Manifestations of GERD 63
Recovery of gastric function after Helicobacter pylori eradication in subjects with body atrophic gastritis: prospective 4-year study 62
Macrohematuria caused by a fall in prothrombin activity as a clinical presentation of celiac disease. (I.F. 1.357) 62
Italian consensus guideline for chronic pancreatitis. 62
P.154 CONNECTIONS BETWEEN GENETICS AND CLINICAL DATA: ROLE OF MCP-1, CFTR, AND SPINK-1 IN THE SETTING OF ACUTE, ACUTE RECURRENT, AND CHRONIC PANCREATITIS 62
PA.7 CLINICAL VARIABILITY IN THE PRESENTATION OF THE GASTROESOPHAGEAL REFLUX DISEASE BEFORE THE HP ERA (STUDY FROM 1975 TO 1995) 62
Assessment of H. pylori-related chronic gastritis by means of serum pepsinogens and oral sucrose 62
M1262 Baseline Symptoms in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) 62
Chronic atrophic gastritis (GAC) and Helicobacter pylori infection eradication: a 3 years follow-up 61
‘Serological Biopsy’ in first degree relatives of patients with gastric cancer, affected by Helicobacter pylori 61
GENETICS OF CHRONIC PANCREATITIS 61
P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROP H IC GASTRITIS 61
THE SIZE OF PANCREATIC PSEUDOCYST DOES NOT INFLUENCE THE OUTCOME OF INVASIVE TREATMENTS 61
Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients. 61
Prevalence of CagA status in an high risk area for gastric carcinoma 61
The contribution of MHC region genes in the genetic predisposition to primary sclerosing cholangitis (PSC) 61
Early epigastric pain after PPI administration: exacerbation of Helicobacter pyolori corpus gastritis? 61
Serum pepsinogen II as a biomarker in management of H. pylori infection 61
Serum pepsinogen II and Gastrin-17 (G-17) as markers of NSAIDS gastropathy 60
Clinical usefulness of gastropanel (sPGI, sPGII, Gastrin, H. pylori specific IgG) in assessment of H. pylori infection in children 60
Symptoms in GERD, NERD and gastroduodenal reflux 60
Relationship between direct and indirect methods for diagnosis of H.pylori infection 60
Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. 60
A new curcumin-based one week therapy for eradication of H. pylori infection 60
Hyperbilirubinemia: does it matter? 60
TAP genes, coding for the transporters associated with antigen processing, contribute to the genetic predisposition to primary sclerosing cholangitis (PSC) 60
P.10 “GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD: PROSPECTIVE SIX MONTHS CLINICAL STUDY 60
Lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: results of an open randomized trial 59
HLA-DRB1*04 Allele contribute to the genetic susceptibility of chronic pancreatitis 59
P.1.292: SYMPTOMATOLOGICAL PATTERN IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD), IRRITABLE BOWEL SYNDROME-DIARRHOEA (IBS-D), AND IBS-D PLUS SUDD 59
DO PREBIOTICS RELIEVE CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-C) SYMPTOMS? A RANDOMIZED SINGLE BLINDED STUDY 58
Totale 6.880
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.053
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.053
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020957 0 0 0 0 0 288 227 42 136 122 19 123
2020/2021852 17 123 112 2 115 8 108 5 189 32 133 8
2021/2022777 14 15 10 36 43 17 80 108 32 87 92 243
2022/20232.618 294 253 169 234 238 325 7 188 797 9 81 23
2023/2024784 53 84 24 22 56 217 40 61 18 48 77 84
2024/20251.352 83 187 214 148 364 356 0 0 0 0 0 0
Totale 9.359